… /valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure …
E Straburzyńska-Migaj, J Nessler… - Polish Heart …, 2017 - journals.viamedica.pl
… and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic
heart failure … the special contribution of the Heart Failure Association (HFA) of the ESC. Eur …
heart failure … the special contribution of the Heart Failure Association (HFA) of the ESC. Eur …
Sacubitril/valsartan across the spectrum of ejection fraction in heart failure
SD Solomon, M Vaduganathan, B L. Claggett… - Circulation, 2020 - Am Heart Assoc
… chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart
failure … with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur …
failure … with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur …
Cost-utility analysis of sacubitril/valsartan use compared with standard care in chronic heart failure patients with reduced ejection fraction in South Korea
SK Park, SH Hong, HJ Kim, S Kim, EK Lee - Clinical therapeutics, 2019 - Elsevier
… valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is a possible
treatment option for chronic heart failure … -effectiveness of sacubitril/valsartan use in South Korea …
treatment option for chronic heart failure … -effectiveness of sacubitril/valsartan use in South Korea …
Pharmacokinetics of multiple doses of valsartan in patients with heart failure
PP Prasad, CM Yeh, P Gurrieri, R Glazer… - Journal of …, 2002 - journals.lww.com
… valsartan regimens in heart failure, including 40, 80, and 160 mg administered every 12 h.
The influence of age, New York Heart … of valsartan in heart failure patients were evaluated. …
The influence of age, New York Heart … of valsartan in heart failure patients were evaluated. …
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
… Figure 1 Mechanism of action of sacubitril/valsartan in heart failure. Notes: Heart failure …
LCZ696 is composed of two molecular moieties, the angiotensin receptor blocker valsartan …
LCZ696 is composed of two molecular moieties, the angiotensin receptor blocker valsartan …
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial
IS Anand, TS Rector, M Kuskowski… - … : Heart Failure, 2008 - Am Heart Assoc
… The present study is a secondary analysis of the Valsartan Heart Failure Trial (Val-HeFT) …
time on the effectiveness of treatment with valsartan on morbidity and mortality in patients with …
time on the effectiveness of treatment with valsartan on morbidity and mortality in patients with …
Sacubitril/valsartan (LCZ696) in heart failure
Y Khder, V Shi, JJV McMurray, MP Lefkowitz - Heart Failure, 2017 - Springer
… 21% less risk for first hospitalization for heart failure, and 16% less risk … Concerning tolerability,
the sacubitril/valsartan group had … /valsartan has been endorsed by the latest heart failure …
the sacubitril/valsartan group had … /valsartan has been endorsed by the latest heart failure …
[HTML][HTML] Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of …
H Tsutsui, S Momomura, Y Saito, H Ito, K Yamamoto… - Journal of …, 2017 - Elsevier
… chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic
heart failure … Developed with the special contribution of the Heart Failure Association (HFA) of …
heart failure … Developed with the special contribution of the Heart Failure Association (HFA) of …
Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial
… In patients with heart failure with reduced ejection fraction, sacubitril/valsartan significantly
… mortality, and heart failure hospitalization, sacubitril/valsartan may improve limitations in …
… mortality, and heart failure hospitalization, sacubitril/valsartan may improve limitations in …
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
V Gregorietti, TL Fernandez, D Costa, EO Chahla… - Cardio-oncology, 2020 - Springer
… Sacubitril/valsartan (LCZ-696) is a … of chronic heart failure with reduced ejection fraction.
The PARADIGM-HF study was the trial that led to the approval of the use of sacubitril/valsartan …
The PARADIGM-HF study was the trial that led to the approval of the use of sacubitril/valsartan …